TUB-040 for advanced ovarian or lung cancer after standard treatments fail
Part of Cancer, Hormones & metabolism, Lungs & breathing, Women’s health & pregnancy clinical trials.
This study tests a new drug called TUB-040 for people with ovarian cancer that has stopped responding to platinum chemotherapy, or with a type of lung cancer that has returned or spread. The drug is designed to target cancer cells and deliver a powerful anti-cancer agent directly to them, potentially slowing the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older, and not pregnant or breastfeeding
- Your cancer is advanced and standard treatments have stopped working or are not expected to help
- You have at least one tumor that can be measured on a scan
- You are able to carry out normal daily activities with little or no help (ECOG score 0 or 1)
- You are willing to provide a sample of your tumor tissue (or allow us to use an older sample) for testing
- You are willing to have a special lung scan and breathing tests at the start of the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.
This study tests a new medicine called TUB-040, given together with standard ovarian cancer drugs like carboplatin and bevacizumab. It is for women with ovarian cancer that has returned after responding to platinum-based chemotherapy and is growing again. The goal is to see if this combination can help control the cancer.
This trial tests an experimental drug called TUB-040 for people with advanced non-small cell lung cancer that has spread or cannot be removed by surgery. The drug is designed to target and attack cancer cells while sparing healthy tissue, potentially slowing the cancer's growth.
This trial tests a new drug (DC05F01) for people with ovarian cancer that has come back after platinum treatment, or for those with other advanced solid tumors that haven't responded to standard therapies. It aims to see if the drug is safe and effective.
This study tests an experimental drug called TJ102 for people with advanced ovarian cancer or other solid tumors that have grown despite prior treatments. It aims to see if the drug is safe and effective.
This study tests a new investigational drug called JSKN003 for people with ovarian cancer that has stopped responding to standard chemotherapy. The goal is to see if this drug can help shrink tumors and slow down the cancer's growth.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.